Genmab — Juni 2013
-
and growing
-
core market I like
-
vi har fået at vide at de er low double digit og stigende
-
og lov double digit og faste for Lixilan
-
dog af hele kombinationsproduktet
-
RegulatorydecisioninJapanexpectedmid-2013
-
så der er lidt triggers her også
-
2k
-
lige i overkanten af hvad jeg ville ind med
-
men salgstallene er meget bedre end jeg havde troet
-
jeg hader danske bank lige nu. virkeligt
-
De siger at prisen på lyxumia er 1,2 gange Byetta og Victoza er 1,8 gange Byetta dvs. Victoza sælges 50% dyrere end Lyxumia.
-
zealand får royalties
-
der er 100% margin på det skidt
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind